blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2279207

EP2279207 - HUMANIZED ANTIBODIES AGAINST HUMAN INTERFERON-ALPHA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.07.2016
Database last updated on 28.09.2024
Most recent event   Tooltip17.08.2018Lapse of the patent in a contracting state
New state(s): BG		published on 19.09.2018  [2018/38]
Applicant(s)For all designated states
Argos Therapeutics, Inc.
4233 Technology Drive
Durham, NC 27704 / US
[2011/10]
Former [2011/05]For all designated states
Novo Nordisk A/S
Novo Allé
2880 Bagsværd / DK
Inventor(s)01 / SVENSSON, Lars Anders
Roskildevägen 17B
217 46 Malmö / SE
02 / PADKJÆR, Søren
Rosen Allé 2
Hareskov
3500 Værløse / DK
03 / FRIEDRICHSEN, Birgitte
Agertoften 12
2800 Gentofte / DK
04 / OLSEN KROGH, Berit
Vamdrupvej 57
2610 Rødovre / DK
05 / LUND PEDERSEN, Inger
Vangsåvej 10
2720 Vanløse / DK
06 / FLECKNER, Jan
c/o Novo Nordisk a/s
Novo Allé
2880 Bagsværd / DK
 [2015/37]
Former [2011/05]01 / SVENSSON, Lars Anders
Roskildevägen 17B
S-217 46 Malmö / SE
02 / PADKJÆR, Søren
Rosen Allé 2 Hareskov
DK-3500 Værløse / DK
03 / FRIEDRICHSEN, Birgitte
Agertoften 12
DK-2800 Gentofte / DK
04 / OLSEN KROGH, Berit
Vamdrupvej 57
DK-2610 Rødovre / DK
05 / LUND PEDERSEN, Inger
Vangsåvej 10
DK-2720 Vanløse / DK
06 / FLECKNER, Jan
c/o Novo Nordisk a/s Novo Allé
2880 Bagsvaerd / DK
Representative(s)HGF
HGF Limited
Mill House
North Street
York YO1 6JD / GB
[N/P]
Former [2015/37]HGF Limited
Saviour House
9 St. Saviourgate
York YO1 8NQ / GB
Former [2011/05]Harrison Goddard Foote
106 Micklegate
York, Yorkshire YO1 6JX / GB
Application number, filing date09742079.806.05.2009
[2011/05]
WO2009EP55448
Priority number, dateEP2008010384707.05.2008         Original published format: EP 08103847
[2011/05]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009135861
Date:12.11.2009
Language:EN
[2009/46]
Type: A2 Application without search report 
No.:EP2279207
Date:02.02.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 12.11.2009 takes the place of the publication of the European patent application.
[2011/05]
Type: B1 Patent specification 
No.:EP2279207
Date:09.09.2015
Language:EN
[2015/37]
Search report(s)International search report - published on:EP28.01.2010
ClassificationIPC:C07K16/24, C07K16/46
[2011/05]
CPC:
C07K16/249 (EP,US); A61P1/04 (EP); A61P1/14 (EP);
A61P1/16 (EP); A61P11/00 (EP); A61P11/02 (EP);
A61P11/06 (EP); A61P13/12 (EP); A61P17/00 (EP);
A61P17/06 (EP); A61P19/02 (EP); A61P21/00 (EP);
A61P25/00 (EP); A61P29/00 (EP); A61P3/10 (EP);
A61P31/14 (EP); A61P31/20 (EP); A61P37/00 (EP);
A61P37/02 (EP); A61P37/06 (EP); A61P37/08 (EP);
A61P5/14 (EP); A61P7/04 (EP); A61P7/06 (EP);
A61P9/00 (EP); C07K16/464 (EP,US); C07K2317/34 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2015/37]
Former [2011/05]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:HUMANISIERTE ANTIKÖRPER GEGEN MENSCHLICHES INTERFERON-ALPHA[2011/05]
English:HUMANIZED ANTIBODIES AGAINST HUMAN INTERFERON-ALPHA[2011/05]
French:ANTICORPS HUMANISÉS CONTRE L'INTERFÉRON-ALPHA HUMAIN[2011/05]
Entry into regional phase06.12.2010National basic fee paid 
06.12.2010Designation fee(s) paid 
06.12.2010Examination fee paid 
Examination procedure06.12.2010Examination requested  [2011/05]
27.01.2011Amendment by applicant (claims and/or description)
18.10.2011Despatch of a communication from the examining division (Time limit: M06)
24.04.2012Reply to a communication from the examining division
12.07.2013Despatch of a communication from the examining division (Time limit: M04)
12.11.2013Reply to a communication from the examining division
23.03.2015Communication of intention to grant the patent
31.07.2015Fee for grant paid
31.07.2015Fee for publishing/printing paid
31.07.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.10.2011
Opposition(s)10.06.2016No opposition filed within time limit [2016/33]
Fees paidRenewal fee
11.05.2011Renewal fee patent year 03
29.03.2012Renewal fee patent year 04
28.05.2013Renewal fee patent year 05
26.03.2014Renewal fee patent year 06
27.05.2015Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.05.2009
AT09.09.2015
BE09.09.2015
BG09.09.2015
CY09.09.2015
CZ09.09.2015
DK09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
MC09.09.2015
MK09.09.2015
NL09.09.2015
PL09.09.2015
RO09.09.2015
SE09.09.2015
SI09.09.2015
SK09.09.2015
TR09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
PT11.01.2016
IE06.05.2016
LU06.05.2016
CH31.05.2016
LI31.05.2016
MT31.05.2016
[2018/38]
Former [2018/32]HU06.05.2009
AT09.09.2015
BE09.09.2015
CY09.09.2015
CZ09.09.2015
DK09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
MC09.09.2015
MK09.09.2015
NL09.09.2015
PL09.09.2015
RO09.09.2015
SE09.09.2015
SI09.09.2015
SK09.09.2015
TR09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
PT11.01.2016
IE06.05.2016
LU06.05.2016
CH31.05.2016
LI31.05.2016
MT31.05.2016
Former [2018/29]HU06.05.2009
AT09.09.2015
BE09.09.2015
CY09.09.2015
CZ09.09.2015
DK09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
MC09.09.2015
MK09.09.2015
NL09.09.2015
PL09.09.2015
RO09.09.2015
SE09.09.2015
SI09.09.2015
SK09.09.2015
TR09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
PT11.01.2016
IE06.05.2016
LU06.05.2016
CH31.05.2016
LI31.05.2016
Former [2018/28]HU06.05.2009
AT09.09.2015
BE09.09.2015
CY09.09.2015
CZ09.09.2015
DK09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
MC09.09.2015
MK09.09.2015
NL09.09.2015
PL09.09.2015
RO09.09.2015
SE09.09.2015
SI09.09.2015
SK09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
PT11.01.2016
IE06.05.2016
LU06.05.2016
CH31.05.2016
LI31.05.2016
Former [2017/38]AT09.09.2015
BE09.09.2015
CZ09.09.2015
DK09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
NL09.09.2015
PL09.09.2015
RO09.09.2015
SE09.09.2015
SI09.09.2015
SK09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
PT11.01.2016
IE06.05.2016
LU06.05.2016
CH31.05.2016
LI31.05.2016
Former [2017/07]AT09.09.2015
BE09.09.2015
CZ09.09.2015
DK09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
NL09.09.2015
PL09.09.2015
RO09.09.2015
SE09.09.2015
SI09.09.2015
SK09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
PT11.01.2016
LU06.05.2016
CH31.05.2016
LI31.05.2016
Former [2017/04]AT09.09.2015
BE09.09.2015
CZ09.09.2015
DK09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
NL09.09.2015
PL09.09.2015
RO09.09.2015
SE09.09.2015
SI09.09.2015
SK09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
PT11.01.2016
LU06.05.2016
Former [2017/03]AT09.09.2015
BE09.09.2015
CZ09.09.2015
DK09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
NL09.09.2015
PL09.09.2015
RO09.09.2015
SE09.09.2015
SI09.09.2015
SK09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
PT11.01.2016
Former [2016/39]AT09.09.2015
CZ09.09.2015
DK09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
NL09.09.2015
PL09.09.2015
RO09.09.2015
SE09.09.2015
SI09.09.2015
SK09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
PT11.01.2016
BE31.05.2016
Former [2016/36]AT09.09.2015
CZ09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
NL09.09.2015
PL09.09.2015
RO09.09.2015
SE09.09.2015
SI09.09.2015
SK09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
PT11.01.2016
BE31.05.2016
Former [2016/24]AT09.09.2015
CZ09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
NL09.09.2015
PL09.09.2015
RO09.09.2015
SE09.09.2015
SK09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
PT11.01.2016
Former [2016/23]CZ09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
NL09.09.2015
RO09.09.2015
SE09.09.2015
SK09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
Former [2016/22]CZ09.09.2015
EE09.09.2015
FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
NL09.09.2015
SE09.09.2015
NO09.12.2015
GR10.12.2015
IS09.01.2016
Former [2016/14]FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
NL09.09.2015
SE09.09.2015
NO09.12.2015
GR10.12.2015
Former [2016/11]FI09.09.2015
HR09.09.2015
LT09.09.2015
LV09.09.2015
SE09.09.2015
NO09.12.2015
GR10.12.2015
Former [2016/09]FI09.09.2015
LT09.09.2015
LV09.09.2015
NO09.12.2015
GR10.12.2015
Former [2016/08]LT09.09.2015
NO09.12.2015
Former [2016/07]LT09.09.2015
Cited inInternational search[A]WO02066649  (GENENTECH INC [US], et al) [A] 1-13 * the whole document *;
 [A]WO2005059106  (MEDAREX INC [US], et al) [A] 1-13 * the whole document *;
 [X]WO2006086586  (BAYLOR RES INST [US], et al) [X] 1-13 * the whole document *;
 [A]WO2008021976  (BAYLOR RES INST [US], et al) [A] 1-13 * the whole document *;
 [A]  - CHUNTHARAPAI ANAN ET AL, "Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, (20010907), vol. 15, no. 5, ISSN 1043-4666, pages 250 - 260, XP002307361 [A] 1-13 * the whole document *
 [A]  - LAZAR GREG A ET AL, "A molecular immunology approach to antibody humanization and functional optimization.", MOLECULAR IMMUNOLOGY MAR 2007, (200703), vol. 44, no. 8, ISSN 0161-5890, pages 1986 - 1998, XP002540093 [A] 1-13 * page 1993, column R, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/j.molimm.2006.09.029
 [A]  - WU H ET AL, "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.", JOURNAL OF MOLECULAR BIOLOGY 19 NOV 1999, (19991119), vol. 294, no. 1, ISSN 0022-2836, pages 151 - 162, XP002540094 [A] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1006/jmbi.1999.3141
 [A]  - KASHMIRI SYED V S ET AL, "SDR grafting--a new approach to antibody humanization.", METHODS (SAN DIEGO, CALIF.) MAY 2005, (200505), vol. 36, no. 1, ISSN 1046-2023, pages 25 - 34, XP002540095 [A] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1016/J.YMETH.2005.01.003
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.